Insulin requires A(2B) adenosine receptors to modulate the L-arginine/nitric oxide signalling in the human fetoplacental vascular endothelium from late-onset preeclampsia

Author(s)

Salsoso, Rocio ^{[1, 2, 3]} ; Mate, Alfonso ^[3] ; Toledo, Fernando ^{[4, 2]} ; Vazquez, Carmen M. ^[3] ; Sobrevia, Luis ^{[2, 3, 5, 6]}

Affiliation

^[1] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Inst Coracao InCor, Sao Paulo, SP - Brazil

^[2] Pontificia Univ Catolica Chile, Cellular & Mol Physiol Lab CMPL, Sch Med, Div Obstet & Gynaecol, Fac Med, Santiago 8330024 - Chile

^[3] Univ Seville, Fac Farm, Dept Fisiol, E-41012 Seville - Spain

^[4] Univ Bio Bio, Fac Sci, Dept Basic Sci, Chillan 3780000 - Chile

^[5] Sao Paulo State Univ UNESP, Med Sch Fac Med, Sao Paulo - Brazil

^[6] Univ Queensland, Fac Med & Biomed Sci, Ctr Clin Res UQCCR, Herston, Qld 4029 - Australia

• Document type: Journal article
• Source: BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE; v. 1867, n. 1 JAN 1 2021.
• Web of Science Citations: 0

Abstract

Late-onset preeclampsia (LOPE) associates with reduced umbilical vein reactivity and endothelial nitric oxide synthase (eNOS) activity but increased human cationic amino acid (hCAT-1)-mediated L-arginine transport involving A(2A) adenosine receptor in the fetoplacental unit. This study addresses the A(2B) adenosine receptor (A(2B)AR)-mediated response to insulin in the fetoplacental vasculature from LOPE. Umbilical veins and HUVECs were obtained from women with normal (n = 37) or LOPE (n = 35) pregnancies. Umbilical vein rings reactivity to insulin was assayed in the absence or presence of adenosine and MRS-1754 (A(2B)AR antagonist) in a wire myograph. HUVECs were exposed to insulin, MRS-1754, BAY60-6583 (A(2B)AR agonist), NECA (general adenosine receptors agonist) or N-G-nitro-L-arginine methyl ester (NOS inhibitor). A(2B)AR, hCAT-1, total and phosphorylated eNOS, Akt and p44/42(mapk) protein abundance were determined by Western blotting. Insulin receptors A (IR-A) and B (IR-B), eNOS and hCAT-1 mRNA were determined by qPCR. Firefly/Renilla luciferase assay was used to determine -1606 bp SLC7A1 (hCAT-1) promoter activity. L-Citrulline content was measured by HPLC, L-{[}H-3]citrulline formation from L-{[}H-3]arginine by the Citrulline assay, and intracellular cGMP by radioimmunoassay. LOPE-reduced dilation of vein rings to insulin was restored by MRS-1754. HUVECs from LOPE showed higher A(2B)AR, hCAT-1, and IR-A expression, Akt and p44/42(mapk) activation, and lower NOS activity. MRS-1754 reversed the LOPE effect on A(2B)AR, hCAT-1, Akt, and eNOS inhibitory phosphorylation. Insulin reversed the LOPE effect on A(2B)AR, IR-A and eNOS, but increased hCAT-1-mediated transport. Thus, LOPE alters endothelial function, causing an imbalance in the L-arginine/NO signalling pathway to reduce the umbilical vein dilation to insulin requiring A(2B)AR activation in HUVECs. (AU)

• FAPESP's process: 17/26922-2 - The importance of platelet aggregability in different presentations of Coronary Artery Disease: from subclinical Atherosclerosis to Acute Coronary Syndromes
• Grantee: María Del Rocío Salsoso Rodríguez
• Support Opportunities: Scholarships in Brazil - Post-Doctoral